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Effect of the membrane biocompatibility on nutritional parameters in
chronic hemodialysis patients. Malnutrition is highly prevalent in chronic
hemodialysis patients and is an important determinant of their morbidity
and mortality. Several recent studies have suggested that the inflammatory
response associated with the biocompatibility of the dialysis membranes is
a potential contributing factor. In a prospective study of 159 new
hemodialysis patients from two centers randomized to either a low-flux
biocompatible (BCM) membrane or a low-flux bioincompatible (BICM)
membrane, we measured the long-term effects of biocompatibility on
several nutritional parameters, including estimated dry weight, serum
albumin, insulin-like growth factor-i (IGF-1), and prealbumin over 18
months. Our results show that the BCM group had a mean (± SD) increase
in their dry weight of 2.96 6.88 kg at month 12 and 4.36 8.57 kg at
month 18 (P < 0.05 vs. baseline for both), whereas no change in mean
weight was observed in BICM group. Following initiation of hemodialysis,
a significant increase was observed in serum albumin levels in both groups
of patients. However, the biocompatible group had an earlier and more
marked increase in serum albumin levels compared to the BICM group.
The average increase in serum albumin compared to baseline was
consistently greater than 0.25 g/dl after seven months in the BCM group,
but did not reach this level until 12 months after initiation of dialysis in the
BICM group. The difference between the groups was statistically signifi-
cant at months 7, 8, and 10 (P < 0.05, higher in the BCM group).
Furthermore, the overall difference in serum albumin concentration
between the two groups was larger in the center where the dose of dialysis
was equivalent (P < 0.001). A consistently higher value was also observed in
IGF-1 levels for BCM patients compared to BICM group (P NS). In a
further analysis, changes in IGF-1 levels, but not prealbumin, predicted the
subsequent changes in serum albumin. We conclude that biocompatible
hemodialysis membranes favorably impact on the nutritional status of chronic
hemodialysis patients, independently of the flux characteristics of the mem-
branes, and that IGF-1 may be an early marker of nutritional status.
Several studies have reported the high prevalence of protein-
calorie malnutrition and its association with increased morbidity
and mortality in chronic hemodialysis (CHD) patients [1—6].
Specifically, low concentrations of serum albumin, blood urea
nitrogen (BUN), serum creatinine, as well as low relative body wt
are significantly associated with increased risk of death in CFID
patients [7—9].
Several factors that contribute to this high prevalence of poor
nutritional status have been identified. These include anorexia and
decreased nutrient intake, hormonal and metabolic derangements,
and catabolic factors related to the dialysis procedure [10—14]. The
structure of hemodialysis membrane is an emerging and important
aspect of the dialysis procedure that may play a role in this malnu-
trition [15]. Several studies have highlighted the acute catabolic
effects of dialysis membranes that trigger the activation of the
complement system, the so-called bioincompatible membranes [16,
17]; these catabolic properties have been primarily demonstrated by
the excess release of amino acids in both normal subjects and uremic
patients exposed to such membranes.
The favorable effect of biocompatible hemodialysis membranes
on nutritional aspects of CHD patients was further supported
clinically in studies by Lindsay and colleagues in which they
established the link between protein catabolic rate (PCR), a
putative marker of dietary protein intake in stable CHD patients,
and the modality and the dose of dialysis [18, 19]. They also
showed that the type of cJialysis membrane used affected the
nature of the relationship between the dose of dialysis and PCR.
These investigators proposed that for the same dose of dialysis,
patients on a high-flux biocompatible membrane had a higher
PCR than patients on low-flux bioincompatible membranes. Nev-
ertheless, these studies did not establish clearly whether the
improvement in PCR would result in improvement of commonly
measured nutritional parameters, such as serum albumin concen-
trations, weight, or body mass index, Thus, comparative studies
investigating the long-term effects of repetitive exposure to com-
plement activating membranes (independent of their flux charac-
teristics) on nutritional status of CHD patients are lacking.
In this study, we prospectively analyzed the nutritional status of
patients initiating hemodialysis randomly assigned to dialysis
membranes with different complement activating properties but
similar ultrafiltration capabilities. We used several commonly
measured plasma proteins, such as serum albumin, prealbumin,
and insulin-like growth factor 1 (IGF-1), as well as the estimated
dry weight of the patients, to prospectively monitor these differ-
ences in nutritional parameters.
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Patient characteristics
All patients were recruited from Vanderbilt University Medical
Center (VUMC, Nashville, TN, USA) and Dallas Nephrology
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Table 1. Characteristics of patient population
BICM BCM
No. of patients 80 79
Ageyears 54±15 51±14
Sex
Males 51% 48%
Females 49% 52%
Race
Black 46% 48%
White 43% 43%
Other 11% 9%
Etiology of ESRD
Diabetes 49% 43%
Hypertension 15% 24%
Glomerulonephritis 14% 5%
Other 22% 28%
Associates (DNA, Dallas, TX, USA). Informed consent was
obtained according to each institution's Committee for the Pro-
tection of Human Subjects. All patients over 18 years of age and
newly initiated to chronic dialysis therapy during the time period
of 03/01/91 to 12/31/92 were eligible for study participation. No
patient was excluded on the basis of the etiology of renal failure
or any other medical conditions. The demographics of the patients
on different study membranes are outlined in Table 1. There were
no statistically significant differences between treatment groups
regarding age, gender, primary renal disease and comorbid con-
ditions.
Membrane characteristics
The group assigned to biocompatible membrane group were
dialyzed with a low flux polymethylmethacrylate membrane
(PMMA, Toray B2-1.5 Filtryzer, Toray Industries, Tokyo, Japan),
a membrane known to cause low levels of complement activation.
The other (bioincompatible) membrane group was dialyzed with a
cellulosic membrane (T175, Terumo Corporation, Tokyo, Japan),
a membrane known to have high levels of complement activation.
The in vitro urea clearance characteristics (200 mI/mm solution
flow) were higher for the cellulosic membranes (192 mI/mm for
the cellulosic membrane and 183 mI/mm for the PMMA mem-
brane). Ultrafiltration coefficients were 5 mI/hr/mm Hg for
PMMA membrane and 6.0 mI/hr/mm Hg for cellulosic mem-
branes. Both centers reused dialyzers with bleach and formalde-
hyde; the average number of reuses were 10 3 in both centers.
There was no evidence for any loss of albumin in the dialysate
with these dialyzers [14].
Study design
The study was a prospective, randomized design. The enroll-
ment was done in the order that each patient presented for
initiation of dialysis treatment, and the assignment to a BCM or
BICM was done in alternating order. All patients were assigned to
a treatment group within the first week of initiation of outpatient
dialysis therapy. After randomization, each patient was dialyzed
with their assigned membrane type for all outpatient treatments
for a period of 18 months. During the 18 month study period, the
attending nephrologist determined the patient's dialysis prescrip-
tion and estimated dry weight according to his or her own
judgement, and no restrictions or guidelines for long-term patient
management were made.
Duration of study participation
A total of 159 patients were enrolled in the study: 80 in the
BICM group and 79 in the BCM group. Sixty-six patients (43 in
the BICM group and 23 in the BCM group) completed the 18
month study period. The remaining patients dropped out of the
study prior to 18 months for the following reasons: 13 patients
were transferred to other dialysis facilities (6 BICM, 7 BCM), 12
patients were transplanted (9 BICM, 3 BCM), 10 patients were
noncompliant or requested dropout (4 BICM, 6 BCM), 29
patients did not obtain adequate Kt/V with the study dialyzer (4
BICM, 25 BCM), 8 patients changed to peritoneal dialysis (3
BICM, 5 BCM), I BCM patient recovered renal function in the
first month, 8 patients in each group died, and 4 patients dropped
out for other reasons (3 BICM, 1 BCM). The average days in the
study for each group was 413 171 for BICM and 337 208 for
the BCM group.
Outcome measurements
At initiation into the study, and subsequently once a month for
the first year, and then at termination of the study at 18 months,
the estimated dry weight prescribed by the physician was recorded
and serum samples were obtained for analysis of commonly
measured biochemical parameters as well as serum albumin,
serum prealbumin and serum insulin-like growth factor-i (IGF-1)
levels.
Urea kinetics
Urea kinetic modeling was done for each patient every one to
four months, according to each institution's protocol, to obtain
Kt/V as a measure of dialysis adequacy and protein catabolic rate
as a reflection of dietary protein intake. The measurements were
done using commercially available personal computer software
programs. The single pool model was used to measure the Kt/V at
DNA, while double pool kinetics (with samples drawn 20 mm
following termination of dialysis) was performed at VUMC.
Blood chemistries
Common blood chemistries (BUN, creatinine, glucose, sodium,
potassium, chloride, and total C02) were performed using stan-
dard laboratory techniques. Serum albumin was measured by
bromcresol green method using Olympus 800 analyzer (Olympus
Corporation, Lake Success, NY, USA). Serum prealbumin was
measured by nephelometric assay (Behring BN 100 Nephelome-
ter), and serum insulin-like growth factor-I levels were measured
by radioimmunoassay technique following extraction by acid-
ethanol method (Nichols Institute Diagnostics, San Juan Capist-
rano, CA, USA).
Statistical methods
Average values in a population over time was calculated by,
first, calculating the average value for an individual subject, using
all available data for the subject, and then averaging these single
values per subject across subjects. Comparisons within a group
between baseline and subsequent times were assessed using a
paired t-test. Assessment of overall patterns was done using
several different techniques. Comparisons between groups at
specific times used the Wilcoxon Rank Sum test. Individual linear
regression over time was calculated from each subject's data to
assess whether adjusted levels (the intercept) or the pattern over
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time (the slope) were different between the two study groups.
Finally, mixed model analysis of variance [20] was used to analyze
the data in a repeated measures type framework without the
requirement for complete data for each subject. The correlation
was assessed for each individual alone, and then averaged appro-
priately over all subjects. The model specifically incorporates the
repeated measurements in a subject, allowing for one measure-
ment to impact on the next measurement, but with the impact
decreasing over time. Thus, if the correlation for a measurement
from one month to the next was p, then the correlation over two
months would be p2, the correlation over three months would be
p3, and so forth. Since p is inclusive between —1 and +1, the
correlation decreases with increasing time.
Association of changes over time between variables were
assessed using Spearman (Rank) Correlation. All data analyses
was done using SAS statistical software packages (SAS Institute,
Cary, NC, USA). Results are presented as mean SD. A P value
< 0.05 was considered statistically significant.
Results
Adequacy of dialysis
Both study sites routinely measured adequacy of dialysis by
measurement of Kt/V. However, Kt/V was not controlled for
study purposes and final analysis showed that the mean Kt/V was
higher in the BICM group compared to BCM group (1.37 0.29
vs. 1.24 0.27, P < 0.01). A subgroup analysis showed that this
difference was due to a higher KtIV in one of the sites. Specifically,
the mean Kt/V values over the study period for DNA were 1.45
0.27 for BICM and 1.28 0.29 for BCM (single-pool; P < 0.01).
These values for VUMC were 1.14 0.23 for BICM and 1.12
0.19 for BCM (double-pool; P> 0.5); these values correspond to
single pool values of approximately 1.36 for both membranes.
Nutritional measures
Estimated thy weight. Patients dialyzed with a biocompatible
membrane had a significant increase in their estimated dry weight
compared to their baseline weights. The initial estimated dry
weights of the patients in the BCM group and the BICM group
were 72.1 kg and 73.8 kg, respectively. Figure 1 depicts the mean
changes in dry weights for study months 1, 3, 6, 9, 12, and 18 for
both study membranes. As can be seen, the increase in thy weight
in the BCM group was observed beginning at month 6 and became
statistically significant compared to baseline at month 7. The
mean increase in weight was 2.24 6.99 kg in month 12 and 4.36
8.57 kg in month 18, which were both significantly higher than
the baseline dry weight (all P < 0.05). In contrast, no change from
baseline was observed in the mean dry weights of the patients who
were dialyzed with the bioincompatible membrane. The coeffi-
cient of variation of month-to-month changes in estimated dry
weight was relatively constant and was within 5% of SD.
Similar changes were observed in % ideal body wts (IBW) of the
patients. At entry into the study, the patients were on average 4.5%
below their IBW. The mean % ideal body wt increased by 6.5% for
patients dialyzed with biocompatible membranes, whereas the mean
% ideal body wts showed no change (compared to baseline) for the
patients dialyzed with bioincompatible membranes.
Protein catabolic rate (PCR). PCR tended to increase signifi-
cantly in both treatment groups. However, compared to baseline
the absolute increase was significant only in months 4, 7, 9, 10, and
14, only for the BICM group. There was no significant difference
between the groups in change from baseline.
Serum albumin concentration. Serum albumin levels increased
significantly above baseline values in both membrane groups after
the initiation of dialysis. This effect was continuous throughout
the entire study period for both membranes. Figure 2 shows the
changes in serum albumin levels for study months 1, 3, 6, 9, 12,
and 18 for both study membranes. Note however, that there was
an earlier and more marked increase in serum albumin levels in
BCM group compared to the BICM group. In fact, the average
increase in serum albumin was consistently greater than 0.25 g/dl
compared to baseline after seven months in the BCM group, but
did not reach this level until 12 months after initiation of dialysis
in the BICM group. Indeed, at month 7, only 32% of patients on
BICM group had an increase in serum albumin concentration 
0.25 g/dl, whereas twice as many patients (57%) on the BCM
group had an increase in serum albumin  0.25 g/dl compared to
baseline. Also, the absolute levels of serum albumin was signifi-
cantly higher in the BCM group versus BICM group at month 7
(3.82 0.48 g/dl vs. 3.65 0.39 g!dl; P < 0.05), month 8 (3.86
0.41 g/dl vs. 3.69 0.36 g/dl; P < 0.05) and month 10 (3.89 0.34
gJdl vs. 3.73 0.35 g/dl; P < 0.05).
6
5
C)
0
(1)
Months in study
Fig. 1. Average changes in estimated thy weights atmonths 1, 3, 6, 9, 12, and
18 of study patients randomized to different dialyzers: biocompatible () and
bioincompatible (LI); P < 0.05 at months 12 and 18 for biocompatible group.
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Fig. 2. Average serum albumin levels at months 1, 3, 6, 9, 12, and 18 of study
patients randomized to different dialyzers: biocompatible ) and bioincom-
patible (LI).
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We also used the mixed model analysis of variance to analyze
the data for overall differences due to the membrane. There were
significant differences overall between the two membrane groups
for serum albumin (P < 0.001) levels in patients dialyzed at the
center where the Kt/V was the same in both membrane groups,
with the group on BCM having higher serum albumin level. These
results were not found when the centers were combined.
Serum IGF-1 and prealbumin. The changes in serum IGF-1
levels are shown in Figure 3 for both study membranes. Although
a consistently higher value was observed in IGF-1 levels for BCM
patients, this trend was not statistically significant compared to
either baseline or BICM patients, probably due to large SDS in the
measurements of this assay between study patients. Of note, the
changes from baseline for months 3 and 9 were marginally
significant (P = 0.06 and 0.07, respectively) only for BCM
patients. There was also a marginal difference in IGF-1 levels
between BCM and BICM at month 9 (236 119 ng/ml for BCM
vs. 191 100 ng/ml for BICM; P = 0.09). On the other hand, no
significant trend was observed in prealbumin levels in either BCM
or BICM patients.
We again used the mixed model analysis of variance to analyze
the data for overall differences for IGF-1 and prealbumin levels
between the two membrane groups. There were significant differ-
ences overall between the two membrane groups for IGF-1 (P <
0.05) and prealbumin (P < 0.025) levels in patients dialyzed at the
center where the Kt/V was the same in both membrane groups,
with the group on BCM having higher serum IGF-1 and prealbu-
mm levels. These results were not found when the centers were
combined.
Correlation analysis of serum albumin with IGF-i and Prealbu-
mm. In an attempt to define an association between the changes
in serum albumin and IGF-1 or prealbumin (separately), we
performed correlation analysis as described in statistical methods
section. The analysis shows that the early changes in IGF-1 levels
from months I to 6 were significantly associated with changes in
serum albumin from baseline to subsequent time points (Table 2).
This relationship was not observed between serum albumin and
prealbumin levels.
Discussion
The results of our study demonstrate that the biocompatibility
of hemodialysis membranes, assessed by their complement acti-
Table 2. Correlation analysis between the changes in insulin-like
growth factor 1 (IGF-1) levels from month 1 to month 3 (MI-M3) and
to month 6 (Mi-Mo), and subsequent changes in serum albumin levels
SAIb Mi-M3 Mi-M6 M1-M9 M1-M12 M1-M18
IGF Corr. coef 0.218 0.126 0.150 0.143 0.076
M1-M3
IGF
P value
Corr. coef.
<0.05
N/A
> 0.1
0.288
>0.1
0.231
> 0.1
0.257
> 0.1
0.238
M1-M6
P value N/A <0.01 <0.05 <0.05 0.07
vating properties, improves the long-term results of several nutri-
tional indices in chronic hemodialysis patients. The beneficial
effects of biocompatibility on nutritional indices is suggested by an
early and more pronounced increase in serum albumin level, a
significantly higher weight gain, an increase in % ideal body wt
and substantially higher serum IGF-1 levels. These improvements
were seen in the group of patients on biocompatible dialyzers
using membranes that had lower ultrafiltration and sieving coef-
ficients for middle molecules, and which, because of their limited
surface area, resulted in a lower dose of dialysis.
The adverse effect of complement activating membranes on
amino acid and protein metabolism was previously suggested by
experimental data by Gutierrez and colleagues, in both normal
volunteers and CHD patients [16, 17]. Specifically, they showed
that membranes that resulted in higher complement activation
were associated with increased amino acid release from periph-
eral muscle tissue, consistent with increased protein catabolism;
this adverse effect was not observed during dialysis with biocom-
patible membranes.
The mechanism by which activation of complement pathway
results in increased protein catabolism is not clear. Production of
cytokines, such as interleukin-1 and tumor necrosis factor-alpha
(TNF-a) may induce muscle protein degradation and excess
amino acid release [21—23]. In these studies, the release of amino
acids during dialysis with bioincompatible membranes was most
prominent at six hours after the initiation of hemodialysis [16], a
time period consistent with activation of monocytes, and subse-
quent release of cytokines and their action on muscle cells [15].
Complement activation has been shown to result in increased
transcription of TNF-a, and in a recent study by Canivet and
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Fig. 3. Average serum insulin-like growth factor-i
levels at months 1, 3, 6, 9, and i8 of study
patients randomized to different dialyzers:
biocompatible (N) and bioincompatihle (LI).
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co-workers increased serum TNF-a levels were reported in CHD
patients dialyzed with a complement activating membrane [24].
These observations are further supported by the studies by
Lindsay and co-workers who suggested that at a given dialysis
dose patients dialyzed with a biocompatible dialysis membrane
had a higher PCR compared to patients dialyzed with a bioincom-
patible membrane [25]. The results of our study thus confirm that
CHD patients may benefit nutritionally from long-term treatment
with biocompatible membranes. This may well be part of the
explanation for differences in the relative risk of mortality by
membranes with different biocompatibilities [26].
A notable finding of our study is the earlier and more marked
increase in serum albumin levels in BCM patients. Serum albumin
is the most well documented predictor of mortality in CHD
patients [3, 9, 27]. In an analysis of more than 12,000 CHD
patients, Lowrie and Lew reported that the risk of death increased
exponentially as the concentration of serum albumin decreased
[71. Specifically, when compared to a serum albumin of greater
than 4.0 gldl, serum albumin values of 3.5 to 4.0 g/dl resulted in a
twofold increase in the relative risk of death. It is important to
note that this latter value of albumin is in the range of "normal"
for many laboratories. Therefore, a small difference in serum
albumin levels, even in the normal ranges, may affect the relative
mortality risk in CHD patients. This is relevant to our study
patients in that, although small, the increase in serum albumin
concentrations in the patients dialyzed with BCM membrane was
earlier and consistently higher throughout the entire study period.
Furthermore, in one of the centers where the dose of dialysis was
equivalent between two membrane groups, the difference in this
parameter was even more marked. This difference is probably
related to the inflammatory response induced by the bioincom-
patible membranes which can elicit an acute phase protein
response. Such an acute phase reaction has been shown to result
in a reduction in albumin synthesis [28, 29].
A somewhat surprising difference between the two groups of
patients was the significant increase in dry weights (and % ideal
body wts) of BCM patients, compared to the virtual absence of
change in BICM patients. This increase became statistically
significant beginning at month 6, and the difference between the
groups continued to increase until the completion of the study.
Along with serum albumin, increases in dry weight is an important
nutritional marker of CHD patients. Although dry weight is
considered to be an imprecise marker of nutritional status in
CHD patients, it is a valid and important index of nutrition and
mortality in this patient population, as suggested by Lowrie and
colleagues [8]. In an analysis of more than 12,000 CHD patients
for specific variables associated with increasing risk of death, these
authors reported that almost 42% of the patients had weights
below their calculated ideal body wt, and further found that
decreasing percentage of ideal weight was associated with increas-
ing odds of death. Therefore, an increase in body wt (and % ideal
body wt) further substantiates the beneficial effects of biocompat-
ible membranes on nutritional status of CHD patients.
We also prospectively measured the serum concentrations of
IGF-1 and prealbumin in our study patients, two other putative
markers of nutritional status in CHD patients [30, 31]. Although
both IGF-1 and prealbumin have a short half-life and are closely
related to dietary food intake in different patient populations [32],
studies relating these parameters to nutritional status of CHD
patients have been cross sectional, and measurement of these
indices as a continuous variable in association with overall nutri-
tional status are lacking. In this prospective study, there was a
substantial difference between IGF-1 levels of the study patients,
consistent with the trends of serum albumin levels and dry
weights. Specifically, patients dialyzed with biocompatible mem-
branes had a marked increase in mean serum IGF-1 concentra-
tions beginning at month 3, followed by consistently higher levels
throughout the entire study period. In contrast, BICM group
showed no change in their mean serum IGF-1 levels. However, we
were unable to find a similar trend for serum prealbumin levels.
Our study further supports the predictive value of IGF-1 by
defining the significant association between the early changes in
serum IGF-1 levels with subsequent changes in serum albumin
levels. Specifically, the changes in serum IGF-1 levels from
months 1 to 3 and 6 were associated with changes in serum
albumin at subsequent time points. (This relationship was not
observed with serum prealbumin levels.) Since serum albumin has
a long half-life (20 days) and its concentration is affected by shifts
between intra- and extra-vascular spaces, it is considered an
important, but late marker of nutritional status [4]. Our results
suggest that a change in serum IGF-1 concentrations may be an
earlier index for nutritional status of CHD patients, compared to
serum albumin levels. Nevertheless, the validity and importance
of IGF-1 as a predictor of clinical outcome need to be defined
with further studies.
Protein catabolic rate was another nutritional parameter that
we followed in our patient population. There was a significant
increase over time in PCR in both study groups. However, in
contrast to the above-mentioned differences in other nutritional
parameters, this increase was not different between two groups.
This may be related to limited number of observations of PCR,
especially in BCM group, and large variations within patient
groups, or to the lack of relevance of PCR to nutritional intake.
Two other proposed mechanisms that may improve the nutri-
tional status of CHD patients are higher dose of dialysis and
improved middle molecule clearance during dialysis [4, 18, 33, 34].
In our study design, we were able to separate the effects of middle
molecule clearance by using low-flux dialyzers in both study
groups. However, the mean dose of dialysis, measured by Kt/V,
was significantly higher in BICM group. Based on previous
studies, a higher dialysis dose would be expected to improve
nutritional status of those patients [18, 34]. If true, this further
highlights the importance of biocompatibility on the long-term
nutritional parameters of the study groups, since a more favorable
nutritional status was observed in BCM group, despite having a
lower Kt/V in comparison to BICM group. This hypothesis is
further supported by the more marked difference in nutritional
parameters between the two membrane groups in the center with
equivalent dose of dialysis.
In summary, our study suggests that biocompatibility of hemo-
dialysis membranes is an important factor that affects the nutri-
tional status of CHD patients. Hemodialysis patients dialyzed
long-term with a biocompatible membrane have higher serum
albumin and IGF-1 levels, and significantly increase their body wt,
as compared to patients dialyzed with a bioincompatible mem-
brane. In an additional analysis, our results show that serum
IGF-1 levels are predictive of changes in serum albumin levels.
The effects of these findings on subsequent mortality and morbid-
ity of these patient groups needs to be determined with further
studies,
556 Parker et at: Influence of membrane biocompatibilily on nutrition
Acknowledgments
This study is partly supported by an extramural grant from Baxter
Healthcare Corporation and NIH Grant No. DK-45604-03. Dr. Ikizier is
a recipient of International Society of Nephrology/American Society of
Nephrology Fellowship Training Award. The support of the staff of
Dialysis Clinics, Inc. and Dallas Nephrology Associates is gratefully
acknowledged. We also thank the patients for participating in this study.
Reprint requests to Raymond M Hakim, MD., Ph.D., Vanderbilt Univer-
shy Medical Center, 1161 21st Ave. S. & Garland, Division of Nephrology,
S-3307 MCN, Nashville, Tennessee 37232-2372, USA.
References
1. Acci-nRDo SR, MOORE LW, LATOUR PA: Malnutrition as the main
factor in morbidity and mortality of hemodialysis patients. Kidney mt
24(Suppl 16):S199—S203, 1983
2. BLUMENKRANTZ MJ, KOPPLE JD, GUTMAN RA, CHAN YK, BARBOUR
GL, ROBERTS C, SHEN FH, GANDHI VC, TUCKER CT, CURTIS FK,
COBURN JW: Methods for assessing nutritional status of patients with
renal failure. Am J Clin Nutr 33:1567—1585, 1980
3. GOLDWASSER P, MITrMAN M, ANTIGNANI A, BURREL D, MICHEL M,
COLLIER T, AVRAM MM: Predictors of mortality on hemodialysis. J
Am Soc Nephrol 3:1613—1622, 1993
4. HAKIM RM, LEVIN N: Malnutrition in hemodialysis patients. Am J
Kidney Dis 21:125—137, 1993
5. WOLFSON M, STRONG CJ, MINTURN RD, GRAY DK, KOPPLE JD:
Nutritional status and lymphocyte function in maintenance hemodi-
alysis patients. Am J Clin Nutr 37:547—555, 1984
6. YOUNG GA, SWANEPOEL CR, CROFT MR, HOBSON SM, PARSONS FM:
Anthropometry and plasma valine, amino acids, and proteins in the
nutritional assessment of hemodialysis patients. Kidney mt 21:492—
499, 1982
7. LOWRIE EG, LEw NL: Death risk in hemodialysis patients: The
predictive value of commonly measured variables and an evaluation of
death rate differences between facilities. Am JKidney Dis 15:458—482,
1990
8. LOWRIE EG, HUANG WH, LEw NL, LJU Y: The relative contribution
of measured variables to death risk among hemodialysis patients, in
Death on Hemodialysis, edited by FRIEDMAN EA, Amsterdam, Kiuwer
Academic Publishers, 1994, p 121
9. OWEN WF JR, LEW NL, LIu Y, LOWRIE EG, LAZARUS JM: The urea
reduction ratio and serum albumin concentrations as predictors of
mortality in patients undergoing hemodialysis. N Engi J Med 329:
1001—1006, 1993
10. ALVESTRAND A: Nutritional requirements of hemodialysis patients, in
Nutrition and the Kidney, edited by MITCH WE, KLAHR 5, Boston,
Little Brown, 1988, p 180
11. KOPPLE JD: Causes of catabolism and wasting in acute or chronic
renal failure, in Nephrotogy, edited by ROBINSON RR, New York,
Springer Verlag, 1984, p 1498
12. BERGSTROM J, LINDHOLM B: Nutrition and adequacy of dialysis. How
do hemodialysis and CAPD compare? Kidney mt (Suppl 40) 43:S39—
S50, 1993
13. LAZARUS M: Nutrition in hemodialysis patients. Am J Kidney Dis
21:99—105, 1993
14. IKIZLER TA, FLAKOLL PJ, PARKER RA, HAKIM RM: Amino acid and
albumin losses during hemodialysis. Kidney mt 46:830—837, 1994
15. HAKIM RM: Clinical implications of hemodialysis membrane biocom-
patibility. Kidney mt 44:484—494, 1993
16. GUTIERREZ A, ALVESTRAND A, WAHREN J, BERGSTROM J: Effect of in
vivo contact between blood and dialysis membranes on protein
catabolism in humans. Kidney mt 38:487—494, 1990
17. GUTIERREZ A, BERGSTROM J, ALVESTRAND A: Hemodialysis-associ-
ated protein catabolism with and without glucose in the dialysis fluid.
Kidney mt 46:814—822, 1994
18. LINDSAY RM, SPANNER E: A hypothesis: The protein catabolic rate is
dependent upon the type and amount of treatment in dialyzed uremic
patients. Am J Kidney Dis 132:382—389, 1989
19. LINDSAY R, SPANNER E, HEIDENHEIM P, LEFEBURE J, HODSMAN A,
BAIRD J, ALLISON M: Which comes first, Kt/V or PCR—Chicken or
egg? Kidney mt 42(Suppl 38):S32—S37, 1992
20. JENNRICH RI, SCHLUCHTER MD: Unbalanced repeated-measures
models with structured covariance matrices. Biometrics 42:805—820,
1986
21. HIMMELFARB J, HAKIM RM: Biocompatibility and risk of infection in
hemodialysis patients. Nephrol Dial Transplant 9:138—144, 1994
22. HIMMELFARB J, LAZARUS JM, HAKIM RM: Reactive oxygen species
production by monocytes and polymorphonuclear leukocytes during
dialysis. Am J Kidney Dis 17:271—276, 1991
23. FLORES EA, BISTRIAN BA, POMPOSELLI JJ, DINARELLO CA, BLACK-
BURN GL, ISTFAN NW: Infusion of tumor necrosis factor/cachectin
promoted catabolism in the rat. J Cliii Invest 83:1614—1622, 1989
24. CANIvET E, LAVAUD 5, WONG T, GUENOUNOU M, WILLEMIN JC,
POTRON G, CHANARD J: Cuprophane but not synthetic membrane
induces in serum tumor necrosis factor-alpha levels during hemodial-
ysis. Am J Kidney Dis 23:41—46, 1994
25. LINDSAY RM, SPANNER E, HEIDENHEIM P, KORTAS C, BLAKE PG:
PCR, Kt/V, and membrane. Kidney Int 43(Suppl 41):S268—S273, 1993
26. HAKIM RM, STANNARD D, PORT F, HELD P: Effects of the dialysis
membrane on mortality of chronic hemodialysis patients in the U.S.
(abstract) JAm Soc Nephrol 5:451, 1994
27. IsEKI K, KAWAZOE N, FUKIYAMA K: Serum albumin is a strong
predictor of death in chronic dialysis patients. Kidney mt 44:115—119,
1993
28. BALLMER PE, BALLMER-HOFER K, REPOND F, KOHLER H, STUDER H:
Acute suppression of albumin synthesis in systemic inflammatory
disease: An individually graded response of rat hepatocytes. J Histo-
chem Cytochem 40:201—206, 1995
29. KAYSEN GA, RATHORE V, SHEARER GC, DEPNER TA: Mechanisms of
hypoalbuminemia in hemodialysis patients. Kidney mt 48:510—516,
1995
30. OKSA H, AHONEN K, PASTERNACK A, MARNELA KM: Malnutrition in
hemodialysis patients. Scand J Urol Nephrol 25:157—161, 1991
31. CANO N, FEINANDEZ JP, LACOMBE P, LANKESTER M, PASCAL 5,
DEFAYOLLE M, LABASTIE J, SAINGRA 5: Statistical selection of nutri-
tional parameters in hemodialysis patients. Kidney Int 32(Suppl 22):
S178—S180, 1987
32. WATERLOW JC: Metabolic changes, in Protein-Energy Malnutrition,
edited by WATERLOW JC, London, Edward Arnold, 1992, p 83
33. HAKIM RM, BREYER J, ISMAIL N, SCHULMAN G: Effects of dose of
dialysis on morbidity and mortality.AmfKidneyDis 23:661—669, 1994
34. BURROWES DD, LYONS TA, KAUFMAN AM, LEVIN NW: Improvement
in serum albumin with adequate hemodialysis. JRenal Nutr 3:17 1—176,
1993
